A.P. Pharma to Hold Second Quarter Conference Call August 5, 2002
07/29/2002
|
Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Monday, August 5, 2002 to discuss the results and to answer questions.
To participate in the live call by telephone, please dial (888) 803-8290 from the U.S., and for international callers, please dial (706) 634-1287. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 4979246.
Individuals interested in listening to the conference call via the Internet may do so by visiting www.appharma.com. A replay will be available on the Company's Web site for 14 days.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of prescription pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial targeted areas of application for the Company's drug delivery technology include pain management, inflammation, anti-adhesion and protein delivery applications. The Company's product development programs are funded by royalties from topical products currently marketed by pharmaceutical partners and proceeds from the divestiture of its cosmeceutical product lines. For further information visit the Company's Web site at www.appharma.com.
CONTACT:
A.P. Pharma
Gordon Sangster, 650/366-2626
or
Lippert/Heilshorn & Associates (Investor Relations)
Ina McGuinness (imcguinness@lhai.com)
Bruce Voss (bvoss@lhai.com)
310/691-7100
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.